



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Thursday, 18 September 2025

10:00 – 12:00

Scientific Business Meetings

13:00 – 13:55

Session I: Current EBMT recommendations

Chairs: *Tobias Alexander (DE) & Donal McLornan (UK)*

13:00 – 13:15

EBMT recommendations for HCT in MDS

Carmelo Gurnari (IT)

13:15 – 13:30

EBMT recommendations for HCT in autoimmune diseases

Elisa Roldan Galvan (UK)

13:30 – 13:45

EBMT recommendations for CART in autoimmune diseases

Raffaella Greco (IT)

13:45 – 13:55

Panel discussion

13:55 – 15:00

Session II: MDS diagnosis and prognosis

Chairs: *Kavita Raj (UK) & Adriano Venditti (IT)*

13:55 – 14:10

MDS in 2025: a molecular era of diagnostic and prognostic classifiers

Mario Cazzola (IT)

14:10 – 14:25

HCT or not in MDS? How to decide with current prognostic scoring systems

Nico Gagelmann (DE)

14:25 – 14:40

Are we ready for AI to help in the management of MDS?

Adrian Mosquera (ES)

14:40 – 15:00

Panel discussion

15:00 – 15:30

Coffee break

15:30 – 17:00

Session III: MDS treatment

Chairs: *Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)*

15:30 – 15:45

Current treatment algorithm in Lower-risk MDS

Maria Teresa Voso (IT)

15:45 – 16:00

Current treatment algorithm in Higher-risk MDS and the AML/MDS border

Amer Zeidan (US)

16:00 – 16:15

Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint

Jaroslav Maciejewski (US)

16:15 – 16:30

Access to genomics and transplant policies in MDS in Latin-America

Gonzalo Bentolila (AR)

16:30 – 16:45

Case presentation:

Successful Second AlloSCT from Haploidentical Donor with Dosed-Reduced PTCy for MDS Relapse Refractory to HMA and DLI

Giuliano Filippini Velazquez (DE)

16:45 – 17:00

Panel discussion

17:00 – 17:30

Coffee break

17:30 – 19:00

Session IV: Autoinflammation in haematology and beyond

Chairs: *Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)*

17:30 – 17:45

VEXAS: the lynchpin between inflammation and myeloid neoplasia

Carmelo Gurnari (IT)

17:45 – 18:00

CMML and autoimmune/inflammatory conditions

Francesco Onida (IT)

18:00 – 18:15

Incidence and management of HLH in autoimmune diseases

Coralie Bloch (FR)

18:15 – 18:30

Case presentation:

Brisk CAR-T cell expansion following ciltacabtagene autoleucel complicated by neurological changes, polymicrobial infections, and immune effector-cell-associated HLH-like syndrome

Sarah Leone (US)

18:30 – 18:45

Case presentation:

Allo-HCT in VEXAS: a global clinician experience and metanalysis

Syed Ali (AU)

18:45 – 19:00

Panel discussion

For further information, please contact education.events@ebmt.org

Friday, 19 September 2025

09:00 – 10:15

Joint Physician-Nurse session HCT in MDS in 2025

Chairs: Maaïke de Ruijter (NL) & William Arcese (IT)

09:00 – 09:15 Which donor to choose in the PtCy era?
09:15 – 09:30 Bridging or not prior to allo-HCT for MDS?
09:30 – 09:45 Conditioning regimens in the contemporary era
09:45 – 10:00 Issues on maintenance and management of relapse
10:00 – 10:15 Panel discussion

Kavita Raj (UK)
Nicolaus Kröger (DE)
Joanna Drozd-Sokolowska (PL)
Marie Robin (FR)

10:15 – 10:45

Coffee Break

10:45 – 12:15

Session V: HCT in autoinflammation and autoimmunity

Chairs: John Snowden (UK) & Andrea Bacigalupo (IT)

10:45 – 11:00 HCT in VEXAS
11:00 – 11:15 HCT in Behçet's disease
11:15 – 11:30 HCT in systemic sclerosis
11:30 – 11:45 HCT for AID in Brazil: Current Practices
11:45 – 12:00 *Case presentation:*
Characterising peripheral and central immune signatures in patients with aggressive multiple sclerosis treated with autologous haematopoietic stem cell transplantation or high-efficacy disease modifying treatment
12:00 – 12:15 Panel discussion

Donal McLornan (UK)
Mathieu Puyade (FR)
Nicoletta del Papa (IT)
Fernando Barroso Duarte (BR)

Gavin Brittain (UK)

12:15 – 13:15

Lunch break

13:15 – 15:00

Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases

Chairs: Patrizia Chiusolo (IT) & Paolo Muraro (UK)

13:15 – 13:30 Novel treatment approaches in myeloma
13:30 – 13:45 Bispecifics in myeloma: bridging to CAR-T?
13:45 – 14:00 Bone marrow plasma cell landscape in health and disease
14:00 – 14:15 Plasma cell depletion in autoimmune diseases
14:15 – 14:30 *Case presentation:*
Daratumumab for relapse of autoantibody-mediated neurologic autoimmune disease following autologous hematopoietic stem cell transplantation (aHSCT)
14:30 – 14:45 *Case presentation:*
T-cell engager for autoimmune neuropathy
14:45 – 15:00 Panel discussion

Elisa Roldan Galvan (UK)
Patrick Hayden (IE)
Farzin Mashreghi (DE)
Tobias Alexander (DE)

Paulina Piesik (CA)

Jonathan Wickel (DE)

15:00 – 15:30

Coffee break

15:30 – 17:00

Session VII: Novel cellular therapies in autoimmune diseases

Chairs: Simona Sica (IT) & Dominique Farge (FR)

15:30 – 15:45 Bispecific antibodies in rheumatoid arthritis
15:45 – 16:00 CART in rheumatoid arthritis
16:00 – 16:15 CAR-T cell therapies in paediatric autoimmune diseases
16:15 – 16:30 iPS cells for tissue regeneration in autoimmune disease
16:30 – 16:45 *Case presentation:*
Successful treatment of difficult-to-treat ACPA-positive rheumatoid arthritis with anti-CD19 CAR T cell therapy
16:45 – 17:00 Panel discussion

Ricardo Grieshaber (DE)
Doron Rimar (IS)
Marco Becilli (IT)
Richard Burt (US)

Ioanna Minopoulou (DE)



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy
18-20 September 2025

Saturday, 20 September 2025

09:00 – 10:00	Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases Chairs: <i>Claudia Boggione (IT) & Basil Sharrack (UK)</i>	
09:00 – 09:15	Autologous HCT in MS	Alice Mariottini (IT)
09:15 – 09:30	CAR T in MS	Lena Kristina Pfeffer (DE)
09:30 – 09:45	Cellular therapies in other neurologic indications	<i>To be announced</i>
09:45 – 10:00	Panel discussion	
10:00 – 10:35	Poster Tour Chairs: <i>Tobias Alexander (DE) & Donal McLornan (UK)</i>	
10:00 – 10:05	What essential information should be included in a patient information leaflet to effectively guide individuals with Multiple Sclerosis (MS) who are considering or undergoing autologous hematopoietic stem cell transplantation (aHSCT)?	Hannah Young (UK)
10:05 – 10:10	Anti-ROR1 CAR T cells enhanced with safety iCasp9 suicidal gene expression as novel immunotherapy for mantle cell lymphoma	Madalina Nistor (RO)
10:10 – 10:15	Role of cardiovascular risk stratification in patients undergoing autologous stem cell transplantation for multiple myeloma: a real-life, single-centre evaluation	Ambra Fumagalli (IT)
10:15 – 10:20	<i>An Italian cartography of VEXAS-related thrombosis: a 214.2 patient-years two-step study</i>	Giorgia Ranucci (IT)
10:20 – 10:25	Aggressive Systemic Mastocytosis Associated With High Risk Myelodysplastic Syndrome	Lugain Abdalla (UK)
10:25 – 10:30	The Yin and Yang of Bispecific Drugs in Multiple Myeloma	Maria Chiara Quattrocchi (IT)
10:30 – 10:35	<i>Comparing the MTSS and AIPSS-MF Scores for Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Single-Center Experience</i>	Daniele Sannipoli (IT)
10:35 – 10:55	Coffee Break & Poster Tour	
10:55 – 12:15	Session VIII: Immune monitoring post CART and late complications for autoimmune disease Chairs: <i>Franco Locatelli (IT) & Raffaella Greco (IT)</i>	
10:55 – 11:20	Immune monitoring post-CART	Simona Pagliuca (FR)
11:20 – 11:35	Late complications in HCT	Kirill Krigizov (RU)
11:35 – 11:50	Late complications in CART	Maeve O'Reilly (UK)
11:50 – 11:05	Secondary HLH after CART	Matteo Doglio (IT)
11:05 – 12:15	Panel discussion & take-home messages from all the organizers	